Nephrocare Health Services IPO GMP History
Nephrocare Health Services IPO has been listed on December 17, 2025 at a listing price of ₹490, against the issue price of ₹460 — a gain of ₹30 (+6.52%). The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Nephrocare Health Services IPO raised ₹871.05 Cr. through its IPO at a price band of ₹438 – 460 per share, with a lot size of 32 shares. The IPO was open for subscription from 10 Dec 2025 to 12 Dec 2025.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 27 Aug, 12:08 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| No GMP history available yet. | |||||
Nephrocare Health Services IPO dates
Key dates from opening to listing. Today is 30 October.
- Open 10 Dec 2025
- Close 12 Dec 2025
- Allotment 15 Dec 2025
- Refund/credit 16 Dec 2025
- Listing 17 Dec 2025
Nephrocare Health Services IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹460 |
|---|---|
| Listing gain / loss | +₹30 per share |
| Listing date | 17 Dec, 2025 |
| Actual listing price | ₹490 (+6.52%) |
Is Nephrocare Health Services IPO GMP reliable?
Grey market premium for Nephrocare Health Services IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Nephrocare Health Services IPO full review for a fundamentals-based assessment before making any grey market trades.
Nephrocare Health Services IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Nephrocare Health Services IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Nephrocare Health Services IPO
Nephrocare Health Services Limited is a healthcare-focused company established with the objective of providing specialised kidney care services across India. The company was founded by experienced medical professionals and healthcare entrepreneurs who identified the growing need for quality and accessible dialysis treatment. Over the years, it has expanded its presence by setting up centres in hospitals as well as standalone units, building a network that caters to patients suffering from chronic kidney diseases. With a strong focus on clinical quality and patient care, the company has developed a reputation for reliable and standardised treatment protocols.
The company primarily offers dialysis services, including haemodialysis and related renal care treatments, supported by trained medical staff and modern equipment. Its business model is asset-light and partnership-driven, where it collaborates with hospitals to operate dialysis centres within their premises, reducing capital expenditure while expanding reach. Revenue is generated through long-term service agreements and patient volumes. Promoted by professionals with domain expertise, Nephrocare focuses on operational efficiency, affordability, and scalability, aiming to address the rising demand for kidney care services in both urban and semi-urban regions.
Frequently asked
What is the GMP of Nephrocare Health Services IPO?
The current Grey Market Premium (GMP) of Nephrocare Health Services IPO is not yet started or active in the market.
What is the Kostak Price of Nephrocare Health Services IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Nephrocare Health Services IPO is not available.
What is the Subject to Sauda Price of Nephrocare Health Services IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Nephrocare Health Services IPO?
Nephrocare Health Services IPO listed on December 17, 2025 at ₹490, against the issue price of ₹460 — a gain of +6.52%.
How did the GMP of Nephrocare Health Services IPO trend before listing?
The GMP of Nephrocare Health Services IPO was stable in its final days before listing. View the day-wise table above for the complete GMP history.
Explore Nephrocare Health Services IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
